Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has revealed that it has 15 new projects in its development pipeline from its New Therapeutic Entities (NTE) program, launched in late 2012. The NTE program's focus includes innovation in the abuse deterrent delivery of opioids for pain, development in the delivery of a key schizophrenia treatment, and a new targeted release approach to improve the safety profile of a common treatment for Crohn's Disease.
Based on known molecules that are formulated, delivered, or used in a novel way to address unmet patient need and improve adherence and efficacy, the NTE program is a major element in Teva's strategy for growth. It was established to leverage Teva's vast molecular catalogue, advanced technological capabilities and extensive specialty drug development expertise. The program was designed to "industrialize" the process of generating, evaluating and rapidly and cost-effectively developing new specialty medicine concepts, which bring distinct and definite advantages over current therapies.
"Bringing 15 new development programs into the pipeline in one year is exciting," said Teva president of Global R&D and CSO Dr. Michael Hayden. "Moreover, the products we will be developing represent genuine advances on existing therapies, and will deliver real benefit to patients. The rigorous process we have established to identify and evaluate these projects will support successful delivery of these new treatments for the patients that need them."
Published by Globes [online], Israel business news - www.globes-online.com - on December 4, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013